Introduction: Noninvasive biomarkers that capture the total tumor burden could provide important complementary information for precision medicine to aid clinical decision making. We investigated the value of radiomic data extracted from pretreatment computed tomography images of the primary tumor and lymph nodes in predicting pathological response after neoadjuvant chemoradiation before surgery.
Introduction
For patients with NSCLC treated with trimodality therapy (chemoradiation followed by surgery), pathological response is a direct measure of therapeutic response that is assessed at the time of surgery. Pathological response can be used as a surrogate marker to aid clinical decision making. However, the benefits of adding surgery to chemoradiation for stage IIIA NSCLC remain unclear.
1,2 Therefore, noninvasive early predictors of pathological response are needed to identify patients who would most likely benefit from continuing chemoradiation versus proceeding to surgery.
Increasingly, image-based biomarkers have been investigated for use in clinical decision making. 3 In the field of quantitative imaging, radiomics [4] [5] [6] is an emerging discipline that aims to noninvasively characterize the tumor phenotype by using a robust high-throughput extraction of descriptive features from medical images. 7, 8 Ultimately, these features have been used to develop imaging-based biomarkers to provide complementary information to clinical and genomic data for association with clinical outcomes. Most of these imagebased biomarkers have been developed solely on the basis of analyses of patients' primary tumors. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] In locally advanced NSCLC, tumors have a propensity to spread from the primary site to lymph nodes. These involved lymph nodes could have distinct phenotypic characteristics related to biological processes affecting disease spread and, thus, to treatment response. Given this knowledge, there has also been investigation into the textural features of tumors outside the primary site. Computed tomography (CT) textural features were recently shown to be correlated with malignant and benign lymph nodes. 27, 28 To date, however, there have been very few quantitative analyses of NSCLC lymph node features correlated with clinical outcomes. A study from Li et al. 29 that used conventional positron emission tomography features (standard uptake values and volume) demonstrated that adding lymph node information to the primary tumor features increased their predictive performance for overall disease relapse in NSCLC. Analysis of phenotypic characteristics of lymph nodes may be particularly relevant for NSCLC, as lymph node involvement in locally advanced NSCLC is an important predictor of the outcome of patient treatment. [30] [31] [32] Here, we have investigated the value of radiomic data extracted from pretreatment CT images of the primary tumor and lymph nodes in predicting pathological response after neoadjuvant chemoradiation before surgery. This study has important implications for the development of noninvasive biomarkers that will capture the total tumor burden and provide important complementary information for precision medicine to aid clinical decision making.
Methods

Patient Selection
A total of 177 patients with stage II to III NSCLC treated at our institution between 2003 and 2013 with neoadjuvant chemotherapy and radiotherapy (chemoradiation) before surgical resection were included in this institutional review board-approved study. This cohort included a subset of patients who received adjuvant chemotherapy. No exclusion on the basis of histological subtype was applied.
Patients without surgical pathology reports were excluded, leaving 167 patients. Eight patients were excluded for a delay in surgery greater than 120 days after the completion of chemoradiation. An additional 32 patients were excluded on account of a lack of CT imaging or original treatment contours. Clinically involved lymph nodes before neoadjuvant therapy were identified by fludeoxyglucose positron emission tomography (n ¼ 82) or cervical mediastinoscopy (n ¼ 71). Finally, 42 patients without clinically involved lymph nodes or nodes that were indistinguishable from the primary tumor were excluded, resulting in a total of 85 patients who were included in this study.
Follow-up and End Points
Pathological response was assessed at the time of surgery. The amount of residual tumor was classified on the basis of surgical pathology reports as pathological complete response (pCR), microscopic residual disease (MRD), or gross residual disease (GRD). The percent of residual tumor in the pathological sample was not available for this study because of limited pathological reports available at the time of analysis. Follow-up chest CT scans with contrast (unless the patient had a contraindication to contrast [e.g., renal dysfunction]) were performed to assess tumor progression every 3 to 6 months after treatment on the basis of U.S. national guidelines. 33 Three other clinical end points included in this study were overall survival (OS), distant metastasis (DM), and in-field (within the planning target volume of the primary tumor and/or nodal sites) local recurrence. Local control was considered freedom from local recurrence. The time associated with the end point was defined from the treatment start date to the date of the first event (or last date of follow-up for patients with no events).
CT Acquisition and Segmentation
CTs were acquired according to standardized scanning protocols at our institution by using a GE Lightspeed CT scanner (GE Healthcare, Milwaukee, WI) for treatment planning. Tumor segmentation was performed on radiation therapy planning CTs using Eclipse software (Varian Medical System, Palo Alto, CA). The primary tumor site and lymph nodes were contoured by the treating radiation oncologists using both soft tissue and lung windows. Air, vessels, normal tissue, and surrounding organs were subsequently excluded from these contours and then individually verified by an expert radiation oncologist. If a patient presented with more than one clinically positive nodal station, the union of all the stations was analyzed.
Feature Extraction and Selection
Phenotypic radiomic features were extracted from both primary tumors and lymph nodes (Fig. 1A) with an in-house Matlab 2013 toolbox (The Mathworks, Inc., Natick, MA) and 3D Slicer 4.4.0. 34 Voxels were resampled (3 Â 3 Â 3 mm 3 ) before feature extraction to standardize the voxel spacing across the cohort. Additionally, a voxel intensity bin width of 25 Hounsfield units was used for textural features to increase their sensitivity relative to the raw image. A description of the radiomic features can be found in the supplementary material from a previous study. 
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Radiomic-Based Response Prediction in NSCLCFeatures were selected on the basis of stability and variance, resulting in 20 features (10 from the primary site and 10 from the lymph nodes). The feature selection method can be found in Supplement I ( Supplementary Figs. 1-3 ). The selected features, which showed no redundancy ( Supplementary Fig. 4 ), are individually described in Table 1 .
The performances of the radiomic features were then compared against conventional and clinical variables. The two conventional features included in the study were the maximum axial diameter of the primary tumor and the total volume of the primary tumor and lymph node(s). The nine clinical variables included were age, sex, race, performance status, overall stage, T stage, N stage, radiation dose, and chemotherapy sequence.
Statistical Analysis
All statistical analyses were performed with R software, 35 The statistical difference between clinical variables for pCR versus non-pCR was assessed with a chi-square or two-sided Wilcoxon test for categorical or continuous variables, respectively. Survival estimates were calculated by using the Kaplan-Meier method and controlled with a log-rank test. The 3-year survival or event-free probabilities are reported for each pathological response subgroup (pCR, MRD, and GRD). The predictive performance of the radiomic features was assessed by using the survcomp package. 36 The area under the curve (AUC) was computed and reported for each feature as directly or inversely proportional to the risk for experiencing the event (e.g., GRD) as the feature value increased. AUCs from primary tumor and lymph node features are denoted as AUC Prim and AUC LN , respectively. Noether's test was used to compute the p value to evaluate the significance of the AUC from random (AUC ¼ 0.5). p Values were adjusted for multiple hypothesis testing by using the false discovery rate method. 37 Features with an AUC greater than 0.60 and false discovery rate-corrected p value less than 0.05 were considered predictive. Classifications were made by the random forest method with the randomForest package. 38 We compared the performances of the models by using nested cross validation (CV) and returned the AUC (any values less than 0.5 were flipped). The cohort was split, with 70% used for model tuning and training and the remaining 30% used for validation in 100 iterations. Patients were randomized by using a conservative random split with the caret package. 39 Models were generated from the clinical, conventional, radiomics, or combined (radiomics plus clinical) data set.
Significant differences between the performances of the CV models were evaluated with a permutation test. Only a nonexhaustive pairwise list of four hypotheses was investigated: (1) combined greater than radiomics, (2) 
Results
Clinical Characteristics
A total of 85 patients with primary tumor and lymph node involvement were included in this study ( Table 2) . A total of 85 primary sites and 178 lymph nodes were contoured. The patient cohort was 65% female, exhibited predominantly the adenocarcinoma histological subtype (62%), and had a median age of 60 years (range 
Survival Analysis
The median follow-up time was 40.2 months (range 2.7-117 months). The association between pathological response and outcomes was assessed by using the Kaplan-Meier method, and the 3-year event-free probabilities are reported in Table 3 . Although the p values were not significant, there was a trend (Supplemenary Fig. 6 ).
Radiomics Analysis of Pathological Response
First, we investigated the predictive power of the radiomic features for patients likely to respond well to neoadjuvant chemoradiation (pCR vs. non-pCR). The AUCs for all radiomic features ranged from 0.51 to 0.75. Two lymph node features were predictive of pCR (range 0.72-0.75, p ¼ 0.01) (Fig. 2A) . The best radiomic features extracted from the lymph nodes (AUC LN ¼ 0.75) was significantly higher (p ¼ 0.03, permutation test) than the best from primary site (AUC Prim ¼ 0.61). The two predictive lymph node features were high-intensity large area emphasis (HILAE) and zone percentage (ZP), and both were derived from the same underlying texture group, gray level size zone matrix. None of the conventional features were predictive for pCR. Specifically, the total primary tumor and lymph node volume (AUC ¼ 0.58) and primary tumor axial diameter (AUC ¼ 0.56) were not significantly more predictive than random (p ¼ 0.47).
Second, we investigated patients likely to respond poorly to neoadjuvant chemoradiation (GRD vs. non-GRD). The radiomic feature AUCs ranged from 0.50 to 0.67 (Fig. 2B) . Three features were predictive for GRD (all three AUCs ¼ 0.67, p ¼ 0.02), including the lymph node features ZP and HILAE, which were also predictive for pCR. The third feature was sphericity of the primary tumor. The AUCs for the conventional features were moderately better for GRD (range 0.60-0.61) than for pCR; however, none of the conventional features were significantly more predictive than random (p ¼ 0.09). All results can be found in detail in Supplementary Tables 1  and 2 (Supplement II) . Additionally, consistent results were found in subset analysis with patients with lymph node involvement pathologically confirmed through cervical mediastinoscopy (n ¼ 71 [ Supplementary Fig. 7 ) or overall stage III only (n ¼ 83 [ Supplementary Fig. 8]) .
HILAE is sensitive to large flat zones (connecting voxels of similar intensity) and is associated with the filter Wavelet Low-High-High, which highlights fine and coarse textures. Higher HILAE values represent a more homogenous texture. Similarly, ZP is sensitive to the ratio between the flat zone total intensity value and the total number of voxels in the flat zone. ZP is associated with the filter Laplacian of Gaussian -4mm 2 dimensional kernel, which highlights coarse textures. Lower ZP values represent fewer discrete intensity levels accessed in the region of interest and thus, a more homogeneous tumor. For pCR, HILAE was directly proportional to risk and ZP was inversely proportional to risk, indicating an association between homogeneous lymph node texture and pCR. The risk was symmetrical to pCR for these two features for GRD, with more heterogeneous lymph nodes associated with GRD. Moreover, a rounder primary tumor (quantified by its sphericity) was also predictive of GRD and directly proportional to the probability of GRD. It is noteworthy that two of the three unique predictive features were extracted from the lymph nodes. Conventional features were all inversely proportional for GRD, indicating a trend Note: The global differences between groups were assessed with the log-rank test. pCR, pathologic complete response; MRD, microscopic residual disease; GRD, gross residual disease.
that smaller tumors could be associated with poor response to neoadjuvant chemoradiation. However, none of the conventional features were significant (p ¼ 0.09 and 0.047 for pCR and GRD, respectively).
Models' Classification Performance
To evaluate the performance of our models in classifying patients according to their pathological response, we used the random forest method. For pCR classification (Fig. 3A) , the median AUC values were 0.62 for conventional, 0.64 for the clinical, 0.68 for the radiomic, and 0.65 for the combined (radiomic and clinical) models. The radiomic models performed significantly better than conventional models (p ¼ 0.05, permutation test). No other significant differences were found between the performances of the other models (p ¼ 0.24-0.92).
For classification of GRD (Fig. 3B) , the median AUC values were 0.60 for the conventional, 0.69 for the clinical, 0.71 for the radiomics, and 0.73 for the combined models. The combined model had the highest median performance and performed significantly better than the radiomic (p ¼ 0.01) and clinical (p ¼ 0.05) models. The radiomic model alone performed better than the conventional models (p ¼ 0.03) but not better than the clinical models (p ¼ 0.19).
Discussion
Radiomics 4,5 is a rising field of quantitative imaging that aspires to capture tumor phenotype characteristics noninvasively by using advanced imaging features. Radiomics may have a critical role in precision medicine, as it can predict clinical end points in patients before treatment. 9, 11 Precision medicine is particularly important for patients with stage III NSCLC, as it is known that multiple forms of local therapy (radiation or surgery) are not beneficial for all patients. Currently, however, there is a lack of methods to predict how each patient will respond before treatment. Therefore, in this study, we sought to apply radiomics for prediction of pathological response by using radiomic features extracted from pretreatment images of primary tumors and lymph nodes in patients with NSCLC. Furthermore, this is the first study, to our knowledge, that investigates the prediction of tumor response by using lymph node imaging features.
By using data mining techniques independent from the outcomes and multiple testing correction, we found two radiomic features that were predictive for responders with a pCR and three that were predictive for GRD. In comparison, clinically used tumor measurements (diameter and volume) were poor predictors of pathological response. This potentially reveals the value of radiomics in predicting tumor susceptibility to chemoradiation. The radiomic features indicated that the sphericity of the primary tumor and homogeneity of the lymph nodes were predictive of pathological response. In addition, lymph node homogeneity has previously been shown to be associated with lymph node status (benign versus malignant) in a study by Bayanati et al. 27 Our results complement this study by demonstrating that homogeneous texture, even within a known malignancy, is further associated with better pathological response. These results show that the lymph node phenotype may contain valuable information for predicting clinical end points.
To validate these results, we generated classification models by using a random forest method based on each feature set. We found that a radiomics model performed significantly better than all other models in predicting pCR and that a model combining clinical and radiomics data was the best at predicting GRD. In contrast, models built from conventional imaging features performed poorly, demonstrating that the size of the lymph nodes and primary tumor was not associated with pathological response. These data suggest that pretreatment conventional imaging assessments or stratification by size or overall stage may not be sufficiently predictive of therapeutic response. Moreover, there are more useful quantitative data to be extracted from medical images than what are currently used clinically.
Despite a large number of studies investigating the relationship between tumor phenotype and clinical outcomes, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] few studies have investigated the potential benefit of adding information about lymph nodes. [27] [28] [29] Such lymph node information may be particularly relevant for patients with locally advanced NSCLC. Multiple clinical trials have shown that pathological lymph node clearance is a strong predictor of outcome. Albain et al. 1 demonstrated in a phase II clinical trial that patients with lymph node clearance had an OS of 34.4 months compared with 19 months for patients with residual lymph node disease at the time of surgery. Similarly, Suntharalingam et al. 32 showed a 2-year OS rate of 75% for patients with mediastinal lymph node clearance versus 52% for patients with residual lymph node disease. Given that this study demonstrates an association between quantitative imaging features and pathological response, such features may aid in the identification of patients who are more likely to have an incomplete local and regional tumor response.
Limitations of this study include the small sample size. Only patients with both lymph node (178) and primary tumor (85) contours available and corresponding surgical pathology reports were included, which greatly limited the number of patients in this study. Our study nevertheless includes a larger cohort than previous lymph node studies [27] [28] [29] (our study had 85 patients, whereas other studies had 25 to 46 patients). An additional limitation for image analysis is the lack of standardization in image acquisition that, without access to raw images, is difficult to control. Yet, despite noise introduced by variations in acquisition protocols, radiomic models have shown consistent and reproducible associations with outcomes in multiple independent data sets. [9] [10] [11] [12] Additionally, we resampled the images by using a common pixel spacing to limit variability across patients and selected stable features by using a test/ retest assessment from the RIDER 40 data set. Finally, our cohort included a small number of clinical overall stage II or nonpathologically confirmed lymph nodes. We showed in the supplementary information that our findings were consistent for each subset.
This study demonstrates that lymph node phenotype can present important information that reflects the underlying patient sensitivity to chemoradiation with a power significantly superior to that offered by the primary tumor site alone. Therefore, radiomic features captured from clinically available imaging modalities offer predictive power superior to that of conventionally reported metrics. Predicting tumor response before initiation of neoadjuvant chemoradiation has potentially significant clinical implications for precision medicine, such as development of adaptive therapy plans on the basis of pretreatment phenotypes.
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